759 completed, 372 unknown, 335 recruiting, 260 terminated. 935 Phase 2, 568 Phase 1, 292 Phase 3, 180 Not applicable, 25 Phase 4.
Follow Non-small Cell Lung Cancer: new trials by email Literature Review of Non-small Cell Lung Cancer trials Research Report on Non-small Cell Lung Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation RC48-ADC, Pyrotinib - Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Not yet recruiting | RemeGen Co., Ltd. | 26 | 2027-12-01 | 2026-09-22 |
| DK222 Study at Hopkins [18F]DK222 radiotracer - Non-Small Cell Lung Cancer, Urothelial Cancer | Phase 1 | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 6 | 2027-01-31 | 2026-09-29 |
| Effects of Supervised Aerobic Exercise on Biomarkers in Patients With nSCLC Receiving Immunotherapy Exercise - Non-Small Cell Lung Cancer, Aerobic Exercise | Not applicable | Not yet recruiting | Izmir Bakircay University | 78 | 2027-01-04 | 2026-10-21 |
| ctDNA-Guided Intraventricular Therapy for CNS Malignancies CSF ctDNA-Guided Clinical Management - Leptomeningeal Disease, Glioblastoma | Not applicable | Not yet recruiting | Alireza Mansouri | 77 | 2027-01-01 | 2026-07-08 |
| A Study Evaluating The Combination of Immunotherapy With Radiotherapy in Non-Small Cell Lung Cancer Investigator Choice Immunotherapy (for example: pembrolizumab, cemiplimab, durvalumab, ipilimumab plus nivolumab), Investigator Choice Chemotherapy (for example docetaxel with or without ramucirumab, gemcitabine, or other National Comprehensive Cancer Network (NCCN)-recommended treatments), Ablative Hypofractionated Radiotherapy - Non-Small Cell Lung Cancer, Metastatic Lung Cancer | Phase 2 | Recruiting | University of Chicago | 39 | 2026-12-12 | 2026-06-16 |
| Docetaxel Plus Plinabulin vs Docetaxel Plus Placebo in Advanced/Metastatic Non-Squamous NSCLC After PD-1/PD-L1 Therapy and Platinum Chemotherapy (DUBLIN-4) Plinabulin, Docetaxel, Placebo (matching plinabulin placebo) - Non-Small Cell Lung Cancer, Non-squamous Non-Small Cell Lung Cance | Phase 3 | Not yet recruiting | BeyondSpring Pharmaceuticals Inc. | 442 | 2026-12-01 | 2026-09-29 |
| TCR1188-ABC Cells in KRAS-mutated Cancers TCR1188-ABC cells, Fludarabine + Cyclophosphamide combination, Tocilizumab - Cholangiocarcinoma, Colorectal Cancer | Phase 1 | Recruiting | University of Pennsylvania | 30 | 2026-12-01 | 2026-10-14 |
| PD-1 Blockade Alone Versus in Combination With Chemotherapy as First Line Therapy in Females With Advanced NSCLC & PD-L1 Expression ≥50% Pembrolizumab, Carboplatin (AUC 5), Cisplatin (75 mg/m²) - Non-Small Cell Lung Cancer | Phase 3 | Not yet recruiting | German Cancer Research Center | 406 | 2026-11-30 | 2026-10-16 |
| Cemiplimab for Clinical Stage I, 2-3.9cm, Non-Small Cell Lung Cancer Cemiplimab, Carboplatin + Pemetrexed/Paclitaxel, Cisplatin - Non-Small Cell Lung Cancer | Phase 2 | Not yet recruiting | Medical University of South Carolina | 38 | 2026-11-01 | 2026-07-22 |
| MRD-Guided Aumolertinib-Based Adjuvant Therapy for Resected EGFR-Mutant NSCLC Aumolertinib, Pemetrexed, Carboplatin - Non-Small Cell Lung Cancer | Not applicable | Not yet recruiting | Peking University People's Hospital | 50 | 2026-11-01 | 2026-10-14 |
| Biomarker Testing to Predict Radiation-Related Heart Disease in Lung Cancer Patients Serum Pro-N-Cadherin Biomarker Assessment, Echocardiogram - Non-Small Cell Lung Cancer, Radiation-Induced Cardiac Disease | Not applicable | Not yet recruiting | Duke University | 50 | 2026-11-01 | 2026-10-09 |
| A Phase 1 Study of IM-1340 in Participants With Advanced Cancer IM-1340 - Colorectal Cancer, Non-Small Cell Lung Cancer | Phase 1 | Not yet recruiting | Immunome, Inc. | 200 | 2026-11-01 | 2026-10-22 |
| Repotrectinib Post-Marketing Surveillance in Korean Patients With ROS1-Positive Non-Small Cell Lung Cancer (NSCLC) or Solid Tumors Harboring a Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion Repotrectinib - Non-Small Cell Lung Cancer | Not yet recruiting | Bristol-Myers Squibb | 10 | 2026-10-31 | 2026-09-30 | |
| A Phase 1, Multicenter Imaging Study of LNTH-2403 in Participants With Locally Advanced or Metastatic Solid Tumors. LNTH-2403 - Imaging, Colorectal Cancer | Phase 1 | Not yet recruiting | Radiopharm Theranostics, Ltd | 16 | 2026-10-30 | 2026-08-12 |
| An Open, Multicenter Phase II Clinical Trial of SHR-A2009 Combined With Other Anti-tumor Therapies for Perioperative Treatment of Resectable Non-small Cell Lung Cancer. adebrelimab + SHR-A2009, paclitaxel or pemetrexed combined with carboplatin +adebrelimab, adebrelimab - Non-small Cell Lung Cancer | Phase 2 | Not yet recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 660 | 2026-10-30 | 2026-10-07 |
| Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer Montanide (Registered Trademark) ISA-51 VG Adjuvant, H1299 Cell Lysates, N-803 - Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma | Phase 1 / Phase 2 | Suspended | National Cancer Institute (NCI) | 30 | 2026-10-28 | 2026-10-23 |
| Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic STRO-006, Pembrolizumab - Head & Neck Squamous Cell Carcinoma, Non-Small Cell Lung Cancer | Phase 1 | Recruiting | Sutro Biopharma, Inc. | 285 | 2026-10-19 | 2026-10-23 |
| A Study of Dato-DXd in Participants With Solid Tumors [TROPION-PanTumor04 (TP04)] Dato-DXd, Enfortumab Vedotin (EV), Pembrolizumab - Urothelial Cancer, Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | Daiichi Sankyo | 268 | 2026-10-16 | 2026-10-22 |
| Quad Shot Radiotherapy Combined With Tislelizumab and Platinum-Based Chemotherapy Before Surgery for Stage II-III Non-Small Cell Lung Cancer Quad Shot Radiotherapy, Tislelizumab, Carboplatin or cisplatin - Non-Small Cell Lung Cancer | Phase 2 | Not yet recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 12 | 2026-10-10 | 2026-09-29 |
| A Phase II Study of HS-20093 Injection Combined With Adebrelimab Versus HS-20093 Injection in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations HS-20093 for Injection, Adebrelimab Injection - Non-Small Cell Lung Cancer | Phase 2 | Recruiting | Hansoh BioMedical R&D Company | 76 | 2026-10-08 | 2026-10-23 |
Showing 20 of 2076. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (2076) · Lung Neoplasms (260) · Colorectal Neoplasms (130) · Melanoma (98) · Neoplasms (94) · Breast Neoplasms (92) · Neoplasm Metastasis (85) · Squamous Cell Carcinoma of Head and Neck (82) · Ovarian Neoplasms (80) · Pancreatic Neoplasms (70) · Carcinoma, Renal Cell (69) · Small Cell Lung Carcinoma (58) · Stomach Neoplasms (56) · Triple Negative Breast Neoplasms (50) · Brain Neoplasms (43)
Carcinoma, Bronchogenic (2072) · Bronchial Neoplasms (2071) · Respiratory Tract Diseases (2069) · Respiratory Tract Neoplasms (2069) · Neoplasms by Site (2068) · Thoracic Neoplasms (2066) · Lung Diseases (2065) · Neoplasms (1982) · Lung Neoplasms (1816) · Neoplasms by Histologic Type (316) · Neoplasms, Glandular and Epithelial (266) · Digestive System Diseases (221) · Digestive System Neoplasms (219) · Carcinoma (204) · Skin and Connective Tissue Diseases (202)
Carboplatin (241) · Pemetrexed (192) · Cisplatin (161) · pembrolizumab (150) · Paclitaxel (146) · Docetaxel (124) · Erlotinib Hydrochloride (103) · Bevacizumab (84) · Gemcitabine (80) · Nivolumab (79) · osimertinib (58) · atezolizumab (55) · durvalumab (54) · Radiotherapy (52) · Drug Therapy (46)
AstraZeneca (62) · Hoffmann-La Roche (57) · Sun Yat-sen University (52) · Eli Lilly and Company (48) · Bristol-Myers Squibb (37) · Pfizer (32) · Merck Sharp & Dohme LLC (31) · Novartis Pharmaceuticals (28) · Betta Pharmaceuticals Co., Ltd. (27) · Hunan Province Tumor Hospital (25) · Genentech, Inc. (24) · Amgen (23) · Memorial Sloan Kettering Cancer Center (21) · Washington University School of Medicine (20) · M.D. Anderson Cancer Center (19)
United States (829) · China (688) · Spain (256) · France (244) · South Korea (224) · Italy (214) · Canada (198) · Germany (190) · Australia (174) · Taiwan (164) · United Kingdom (159) · Japan (149) · Poland (140) · Belgium (123) · Netherlands (117)
Yongchang Zhang, MD (13) · Li Zhang, MD (11) · Ramaswamy Govindan, M.D. (7)
PMID 19692680, PMID 27130468, PMID 28472437, PMID 33241650, PMID 34870327, PMID 35537408, PMID 37419867, PMID 39661917, PMID 40311309, PMID 16014882, PMID 16204011, PMID 17075123, PMID 20493771, PMID 20888135, PMID 21783417, PMID 23948351, PMID 24044794, PMID 26768165, PMID 26906526, PMID 28212993, PMID 28501139, PMID 29563138, PMID 29658848, PMID 30207593, PMID 30596880, PMID 31751012, PMID 32418886, PMID 32736936, PMID 32780660, PMID 33231285, PMID 34952813, PMID 35905860, PMID 35930972, PMID 37256434, PMID 37272513, PMID 37465924, PMID 37879536, PMID 38101437, PMID 38159809, PMID 38172595, PMID 38642841, PMID 38816232, PMID 39369790, PMID 39992021, PMID 40354010, PMID 40421698, PMID 40516821, PMID 42014371, PMID 42214243, PMID 42579028
2023 (40), 2017 (20), 2018 (18), 2015 (16), 2014 (14), 2025 (14), 2019 (13), 2016 (11), 2008 (8), 2005 (3), 2009 (2), P30CA015083 (2), 1UG3CA283652-01 (1), 2004 (1), 5UG1CA189824-08 (1)